• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

    3/31/25 4:00:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care
    Get the next $HAE alert in real time by email

    BOSTON, March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025.

    The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

    A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/4z9yixt9 

    A replay of the conference call and webcast will be available for one year beginning on May 8, 2025 at 11:00 am ET using the conference call webcast link provided in this press release.

    ABOUT HAEMONETICS

    Haemonetics (NYSE:HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

    Investor Contacts:



    Olga Guyette, Vice President-Investor Relations & Treasury

    David Trenk, Manager-Investor Relations

    (781) 356-9763

    (203) 733-4987

    [email protected]

    [email protected] 





    Media Contact:



    Josh Gitelson, Sr. Director-Global Communications



    (781) 356-9776



    [email protected]



     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-sets-date-for-publishing-fourth-quarter-and-fiscal-year-2025-results-may-8-2025-302416068.html

    SOURCE Haemonetics Corporation

    Get the next $HAE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HAE

    DatePrice TargetRatingAnalyst
    2/7/2025$95.00 → $68.00Neutral → Underperform
    BofA Securities
    12/6/2024$116.00Overweight
    Analyst
    11/8/2024$120.00Outperform → Strong Buy
    Raymond James
    9/13/2024$116.00Buy
    CL King
    9/11/2024$85.00Neutral
    BofA Securities
    9/10/2024$112.00Buy
    BTIG Research
    6/12/2024$112.00Hold → Buy
    Needham
    10/13/2022$90.00Buy
    Mizuho
    More analyst ratings

    $HAE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

      Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

      5/8/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System

      First fully absorbable, sutureless closure system designed for large-bore procedures aims to improve procedural efficiency and patient outcomes in structural heart interventions Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced European CE mark approval of the PerQseal® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer. Leveraging Vivasure's PerQseal technology, the PerQseal Elite vascular closure system is designed exclusively for sutureless and fully absorbable large-bore closure follow

      4/22/25 9:36:00 AM ET
      $HAE
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products
    • Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

      BOSTON, March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.

      3/31/25 4:00:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Leadership Updates

    Live Leadership Updates

    See more
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Sotera Health Appoints Christopher Simon to the Board of Directors

      CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

      8/1/24 7:00:02 AM ET
      $HAE
      $SHC
      Medical/Dental Instruments
      Health Care
      Misc Health and Biotechnology Services
    • Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

      BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the

      10/4/22 6:51:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Financial Officer Darecca James covered exercise/tax liability with 654 shares, decreasing direct ownership by 4% to 16,692 units (SEC Form 4)

      4 - HAEMONETICS CORP (0000313143) (Issuer)

      5/5/25 4:16:09 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Chan Frank

      3 - HAEMONETICS CORP (0000313143) (Issuer)

      4/9/25 4:14:53 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • President, Global Plasma & BC Galvin Roy covered exercise/tax liability with 161 shares, decreasing direct ownership by 2% to 7,373 units (SEC Form 4)

      4 - HAEMONETICS CORP (0000313143) (Issuer)

      11/5/24 4:17:29 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Haemonetics Corporation

      SC 13G - HAEMONETICS CORP (0000313143) (Subject)

      11/14/24 1:28:29 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

      SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

      11/12/24 12:54:20 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

      SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

      11/8/24 10:41:07 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    SEC Filings

    See more
    • Haemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - HAEMONETICS CORP (0000313143) (Filer)

      5/8/25 6:03:40 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HAEMONETICS CORP (0000313143) (Filer)

      3/3/25 4:13:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Haemonetics Corporation

      10-Q - HAEMONETICS CORP (0000313143) (Filer)

      2/6/25 6:20:48 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Haemonetics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Haemonetics from Neutral to Underperform and set a new price target of $68.00 from $95.00 previously

      2/7/25 8:24:25 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Analyst initiated coverage on Haemonetics with a new price target

      Analyst initiated coverage of Haemonetics with a rating of Overweight and set a new price target of $116.00

      12/6/24 7:49:19 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics upgraded by Raymond James with a new price target

      Raymond James upgraded Haemonetics from Outperform to Strong Buy and set a new price target of $120.00

      11/8/24 7:51:25 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Financials

    Live finance-specific insights

    See more
    • Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

      Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

      5/8/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

      BOSTON, March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.

      3/31/25 4:00:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

      Financial release accessible online BOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 6, 2025. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BIda08929a4d56464

      2/6/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care